Drug Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Drug Name ARS1620
Trade Name
Synonyms ARS-1620
Drug Descriptions

ARS1620 is a covalent inhibitor of KRAS G12C, which may inhibit ERK activation and proliferation in tumor cells harboring KRAS G12C, particularly in combination with other targeted agents (PMID: 30327306, PMID: 29373830, PMID: 31776128).

DrugClasses KRAS G12C inhibitor 28
CAS Registry Number 1698055-85-4


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
ARS1620 ARS1620 0 0
ARS1620 + Everolimus ARS1620 Everolimus 0 0
ARS1620 + Everolimus + Linsitinib ARS1620 Everolimus Linsitinib 0 0
ARS1620 + Gefitinib ARS1620 Gefitinib 0 0
ARS1620 + Linsitinib ARS1620 Linsitinib 0 0
ARS1620 + Pictilisib ARS1620 Pictilisib 0 0

Additional content available in CKB BOOST